PI
AXSM icon

Putnam Investments’s Axsome Therapeutics AXSM Stock Holding History

Putnam Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$3.62M Sell
45,486
-74,780
-62% -$5M ﹤0.01% 532
2023
Q3 		$8.41M Buy
120,266
+2,959
+3% +$221K 0.01% 333
2023
Q2 		$8.43M Buy
117,307
+2,487
+2% +$183K 0.01% 347
2023
Q1 		$7.08M Buy
114,820
+581
+0.5% +$38.2K 0.01% 380
2022
Q4 		$8.81M Buy
114,239
+1,667
+1% +$99.6K 0.02% 311
2022
Q3 		$5.02M Buy
+112,572
New +$5.62M 0.01% 432

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Putnam Investments's AXSM Position: Q4 2023 in Review

Putnam Investments reduced its Axsome Therapeutics (AXSM) stake by 62% in Q4 2023, selling an estimated $5M and leaving 45,486 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #532.

Putnam Investments first reported a position in AXSM in Q3 2022 and has held it in 6 quarters since. The position peaked at $8.81M in Q4 2022. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Putnam Investments held 45,486 shares of Axsome Therapeutics worth $3.62M as of Q4 2023.
  • Putnam Investments sold 74,780 Axsome Therapeutics shares in Q4 2023, an estimated $5M.
  • Axsome Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #532 holding.
  • Putnam Investments first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • Putnam Investments's Axsome Therapeutics position peaked at $8.81M in Q4 2022.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.